BREAKING
Norwood Financial Crushes Q1 2026 Profit Estimates by 46.9% 18 hours ago Easterly Government Properties Delivers 755.6% Q1 2026 Upside, Revenue Up 16% 18 hours ago Indivior Pharmaceuticals (INDV) Jumps 6.2% to $35.27 18 hours ago Veeco Instruments Drops 5.1% Amid Sector-Wide Selling 18 hours ago Noble Corporation (NE) Jumps 7.7% to $53.33 19 hours ago MaxLinear Plunges 10.7% After Stifel Maintains Buy 19 hours ago Coherent Drops 5.2% Amid Sector-Wide Selling 19 hours ago Valaris Shares Jumping 5.0% on Here’s Why Hold Strategy Is Apt for Transocean Stock for Now 19 hours ago Alliance Resource Partners Misses Q1 2026 EPS by 80.0%, Results 19 hours ago Avis Budget Group Drops 7.1% After JP Morgan Downgrades to Underweight 20 hours ago Norwood Financial Crushes Q1 2026 Profit Estimates by 46.9% 18 hours ago Easterly Government Properties Delivers 755.6% Q1 2026 Upside, Revenue Up 16% 18 hours ago Indivior Pharmaceuticals (INDV) Jumps 6.2% to $35.27 18 hours ago Veeco Instruments Drops 5.1% Amid Sector-Wide Selling 18 hours ago Noble Corporation (NE) Jumps 7.7% to $53.33 19 hours ago MaxLinear Plunges 10.7% After Stifel Maintains Buy 19 hours ago Coherent Drops 5.2% Amid Sector-Wide Selling 19 hours ago Valaris Shares Jumping 5.0% on Here’s Why Hold Strategy Is Apt for Transocean Stock for Now 19 hours ago Alliance Resource Partners Misses Q1 2026 EPS by 80.0%, Results 19 hours ago Avis Budget Group Drops 7.1% After JP Morgan Downgrades to Underweight 20 hours ago
ADVERTISEMENT
JNJ

Johnson & Johnson

$JNJ NYSE May 27, 2026 DMH FY 2026

Investor Toolbox

Listen to Call

Watch or listen to the earnings call recording.

Open Webcast

Read Transcript

Transcript not yet available.

View Infographic

Visual summary of key financial data.

View Infographic

Earnings History

View past quarters and earnings trends.

View History

JNJ Coverage

Event Johnson & Johnson (JNJ) FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA) Apr 27, 2026 Event Johnson & Johnson (JNJ) Sec Form 10Q Apr 23, 2026 Event Johnson & Johnson (JNJ) IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG) Apr 22, 2026 Transcript Johnson & Johnson (JNJ) Q1 2026 Earnings Call Transcript Apr 14, 2026 News Johnson & Johnson (JNJ) Earnings: 1Q26 Key Numbers Apr 14, 2026 News Johnson & Johnson likely to report mixed results for Q1 FY26 Apr 7, 2026 Transcript Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript Jan 26, 2026 Transcript Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript Jan 22, 2026